Anthropic Targets Drug Discovery With AI, Reports 89% Cut in Review Time

Anthropic, the developer of the Claude artificial intelligence assistant, is expanding the use of its technology in the medical sector, with a focus on accelerating drug discovery.

In an announcement dated October 27, 2026, the company reported an 89% reduction in review time. The brief summary did not specify which review process the figure covered or how the reduction was measured.

The move puts medical research among the areas Anthropic is targeting for broader AI use. Faster reviews could help reduce some of the time spent assessing information during drug development.

The reported time saving does not, on its own, establish that medicines can be developed or approved 89% faster. The summary provided no details about particular drugs, clinical trials or regulatory outcomes.